Journal
NATURE
Volume 599, Issue 7886, Pages 544-545Publisher
NATURE PORTFOLIO
DOI: 10.1038/d41586-021-03410-9
Keywords
Policy; Neurodegeneration; Drug discovery; Alzheimer's disease
Categories
Ask authors/readers for more resources
Pharmaceutical companies are submitting their anti-amyloid drug candidates for approval, but concerns remain over the controversial precedent set by Biogen's aducanumab.
Eli Lilly and other pharma firms have begun submitting their anti-amyloid drug hopefuls for approval. But questions linger over the controversial precedent set by Biogen's aducanumab.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available